0001415889-24-004245.txt : 20240216
0001415889-24-004245.hdr.sgml : 20240216
20240216200137
ACCESSION NUMBER: 0001415889-24-004245
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LaSpaluto Michelle
CENTRAL INDEX KEY: 0002001106
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35867
FILM NUMBER: 24650278
MAIL ADDRESS:
STREET 1: C/O CHIMERIX, INC.
STREET 2: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHIMERIX INC
CENTRAL INDEX KEY: 0001117480
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330903395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919.806.1074
MAIL ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
4
1
form4-02172024_010229.xml
X0508
4
2024-02-14
0001117480
CHIMERIX INC
CMRX
0002001106
LaSpaluto Michelle
C/O CHIMERIX, INC.
2505 MERIDIAN PARKWAY, SUITE 100
DURHAM
NC
27713
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Common Stock
2024-02-14
4
S
0
1940
1.0426
D
110999
D
The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award granted on January 17, 2023. The sales of the shares were made pursuant to an automatic sell-to-cover arrangement adopted pursuant to Rule 10b5-1 under the Exchange Act in connection with the grant of such restricted stock unit award.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.04 to $1.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
/s/ Michael Alrutz, Attorney-in-Fact
2024-02-16